Naproxen/phosphatidylcholineAlternative Names: PL-3100
Latest Information Update: 29 May 2015
At a glance
- Originator PLx Pharma
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Arthritis
Most Recent Events
- 09 Jul 2010 Phase-II clinical trials in Arthritis (in volunteers) in USA (PO)